Serum levels of GRO-α are elevated in association with disease activity in patients with Behçet's disease

    loading  Checking for direct PDF access through Ovid



Although the etiology of Behçet's disease (BD) is still unknown, neutrophils are implicated in its pathogenesis. Growth-related oncogene-α (GRO-α) is a potent chemoattractant and activator for neutrophils.


To determine the role of GRO-α in the pathogenesis of BD, we investigated serum GRO-α levels in patients with BD.

Materials and methods

Sera from patients with BD (n = 57) and control subjects (n = 26) were measured by enzyme-linked immunosorbent assay. Serum levels of GRO-α were compared with clinical symptoms.


Patients with BD had significantly elevated serum GRO-α levels compared with healthy controls (121.7 ± 79.2 pg/ml vs. 75.9 ± 20.6 pg/ml, P < 0.01). Concerning the subgroups of BD, serum GRO-α levels in active patients with BD (n = 35) were significantly higher than in inactive patients with BD (n = 22; 139.0 ± 92.8 pg/ml vs. 94.3 ± 36.2 pg/ml, P < 0.05). Also, as seen in previous studies, serum interleukin-8 levels in patients with BD (52.4 ± 81.8 pg/ml) were significantly higher than in controls (13.9 ± 19.7 pg/ml, P < 0.01). Enhanced GRO-α levels correlated with clinical symptoms such as erythema nodosum.


Our results indicate that serum levels of GRO-α are elevated in patients with active stage BD, suggesting that GRO-α may serve as a reliable marker for disease activity of BD.

Related Topics

    loading  Loading Related Articles